Back to Search
Start Over
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
- Source :
- Haematologica, Vol 107, Iss 9 (2022)
- Publication Year :
- 2022
- Publisher :
- Ferrata Storti Foundation, 2022.
-
Abstract
- iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Eligible patients were aged ≥65 years, or
- Subjects :
- Diseases of the blood and blood-forming organs
RC633-647.5
Subjects
Details
- Language :
- English
- ISSN :
- 03906078 and 15928721
- Volume :
- 107
- Issue :
- 9
- Database :
- Directory of Open Access Journals
- Journal :
- Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.39c8b0aa684d82a347ea24d5b709ac
- Document Type :
- article
- Full Text :
- https://doi.org/10.3324/haematol.2021.279012